Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium

Lignende værker

• Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
  af: Matt D. Wasserman, et al.
  Udgivet: (2018-11-01)
• Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
  af: Earnshaw Stephanie R, et al.
  Udgivet: (2012-04-01)
• Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
  af: Matthew Wasserman, et al.
  Udgivet: (2019-03-01)
• Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
  af: Matt Wasserman, et al.
  Udgivet: (2019-03-01)
• Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis
  af: Michele R. Wilson, et al.
  Udgivet: (2020-04-01)